Eurolac Special Precautions

Physicians should carefully weigh the potential risks and benefits of its use on a long term basis. Patients should be instructed to watch for signs of serious GI adverse events and they should be monitored more closely than if they were on another NSAID. For the short-term management of pain (other than postoperative). Ketorolac I.M. is not recommended for longer use (more than 5 days) because of the possibility of increased frequency and severity of adverse reactions associated with the recommended doses and Ketorolac tablet is not recommended for use beyond 7 days & is not recommended for chronic use. Dose should be reduced in elderly and in those weighing less than 50 kg. Ketorolac injection is not recommended as a preoperative medication for support of anesthesia because it inhibits platelet aggregation and may prolong bleeding time and because it possesses no sedative or anxiolytic properties.
In patients with symptoms and signs suggesting liver dysfunction or in whom an abnormal liver test has occurred as a result of ketorolac trometamol therapy the administration of the drug should be discontinued. High oral doses (e.g. 80 or 120 mg/day) are not recommended because risk of serious adverse events are greater with daily dose exceeding the recommended 40 mg (4 tablets) oral per day. Serious G.I. toxicity such as bleeding ulceration and perforation can occur at any time with or without warning symptoms in patients with NSAIDs.
Physicians should be aware that in some patients pain relief may not occur until upwards of 30 minutes after I.V or I.M. administration.
Physicians should be aware of the pharmacological similarity of ketorolac to other NSAIDs that inhibit cyclo-oxygenase and the risk of bleeding particularly in the elderly. It should not be used for epidural or spinal administration.